Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


White Paper Is Actually Branded Promotion, FDA Tells Ipsen

This article was originally published in The Pink Sheet Daily

Executive Summary

Warning letter states that when only one drug (Increlex in this case) provides a therapy discussed in promotional materials, they "effectively promote" the drug even if they do not mention it by name.

You may also be interested in...

Abraxane White Paper Distribution At ASCO Draws FDA Advertising Letter

Celgene says the white paper – which FDA says promotes Abaxane as effective for unapproved uses and superior to Bristol-Myers Squibb’s Taxol – was intended solely for potential business partners interested in nab technology.

Ipsen Acquisition Trifecta Raises North American Stakes

French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.

Tercica Will Transition Patients On iPlex To Increlex Following Insmed Patent Settlement

Insmed will no longer provide iPlex growth hormone to short stature patients but can pursue development of the drug in certain other indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts